References
- 1. S. H. Giordano, D. S. Cohen, A. U. Buzdar, G. Perkins and G. N. Hortobagyi, Breast carcinoma in men: a population-based study, Cancer: Interdisc. Int. J. Am. Cancer Soc.101 (2004) 51–57; https://doi.org/10.1002/cncr.2031210.1002/cncr.2031215221988
- 2. L. W. C. Chow, A. Yun-San Yip, W. T. Y. Loo and M. Toi, Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer, Cancer Lett. 262 (2008) 232–238; https://doi.org/10.1016/j.canlet.2007.12.00310.1016/j.canlet.2007.12.00318248884
- 3. A. M. Farag, A. S. Mayhoub, T. M. Eldebss, A. G. E. Amr, K. A. Ali, N. A. Abdel-Hafez and M. M. Abdulla, Synthesis and structure-activity relationship studies of pyrazole-based heterocycles as antitumor agents, Arch. Pharm. 343 (2010) 384–396; https://doi.org/10.1002/ardp.20090017610.1002/ardp.20090017620397210
- 4. Z. Sahin, M. Ertas, B. Berk, S.N. Biltekin, L. Yurttas and S. Demirayak, Studies on non-steroidal inhibitors of aromatase enzyme; 4-(aryl/heteroaryl)-2-(pyrimidin-2-yl) thiazole derivatives, Bioorg. Med. Chem.26 (2018) 1986–1995; https://doi.org/10.1016/j.bmc.2018.02.04810.1016/j.bmc.2018.02.04829525337
- 5. R. J. Santen, E. Samojlik, A. Lipton, H. Harvey, E. B. Ruby, S. A. Wells and J. Kendall, Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer, Cancer39 (1977) 2948–2958; https://doi.org/10.1002/1097-0142(197706)39:6<2948::AID-CNCR2820390681 >3.0.CO;2-9
- 6. R. J. Santen, S. Santner, B. Davis, J. Veldhuis, E. Samojlik and E. Ruby, Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma, J. Clin. Endocrinol. Metab.47 (1978) 1257–1265; https://doi.org/10.1210/jcem-47-6-125710.1210/jcem-47-6-1257263348
- 7. M. Ertas, Z. Sahin, B. Berk, L. Yurttas, S.N. Biltekin and S. Demirayak, Pyridine-substituted thiazolylphenol derivatives: Synthesis, modeling studies, aromatase inhibition, and antiproliferative activity evaluation, Arch. Pharm.351 (2018) 1700272; https://doi.org/10.1002/ardp.20170027210.1002/ardp.20170027229522642
- 8. P. Furet, C. Batzl, A. Bhatnagar, E. Francotte, G. Rihs and M. Lang, Aromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compounds, J. Med. Chem.36 (1993) 1393–1400.
- 9. C. D. Jones, M. A. Winter, K. S. Hirsch, N. Stamm, H. M. Taylor, H. E. Holden, J. D. Davenport, E. V. Krumkalns and R. G. Suhr, Estrogen synthetase inhibitors. 2. Comparison of the in vitro aromatase inhibitory activity for a variety of nitrogen heterocycles substituted with diarylmethane or diarylmethanol groups, J. Med. Chem.33 (1990) 416–429.10.1021/jm00163a0652296032
- 10. A. Cavalli and M. Recanatini, Looking for selectivity among cytochrome P450s inhibitors, J. Med. Chem. 45 (2002) 251–254; https://doi.org/10.1021/jm015567k10.1021/jm015567k11784128
- 11. M. L. Fascio, C. S. Sepúlveda, E. B. Damonte and N. B. D’Accorso, Synthesis and antiviral activity of some imidazo [1,2-b][1,3,4] thiadiazole carbohydrate derivatives, Carbohydr. Res.480 (2019) 61–66; https://doi.org/10.1016/j.carres.2019.05.00310.1016/j.carres.2019.05.00331176191
- 12. J. Chen, C. Yi, S. Wang, S. Wu, S. Li, D. Hu and B. Song, Novel amide derivatives containing 1,3,4-thiadiazole moiety: Design, synthesis, nematocidal and antibacterial activities, Bioorg. Med. Chem. Lett. 29 (2019) 1203–12010; https://doi.org/10.1016/j.bmcl.2019.03.01710.1016/j.bmcl.2019.03.01730902458
- 13. G. Serban, Future prospects in the treatment of parasitic diseases: 2-Amino-1,3,4-thiadiazoles in leishmaniasis, Molecules24 (2019) 1557–1579; https://doi.org/10.3390/molecules2408155710.3390/molecules24081557651467331010226
- 14. D. C. Sekhar, D. V. Rao, A. T. Rao, U. L. Kumar and A. Jha, Design and synthesis of 1,3,4-thiadiazole derivatives as novel anticancer and antitubercular agents, Russ. J. Gen. Chem.89 (2019) 770–779; https://doi.org/10.1134/S107036321904022410.1134/S1070363219040224
- 15. A. Foroumadi, Z. Kargar, A. Sakhteman, Z. Sharifzadeh, R. Feyzmohammadi, M. Kazemi and A. Shafiee, Synthesis and antimycobacterial activity of some alkyl [5-(nitroaryl)-1,3,4-thiadiazol-2-ylthio] propionates, Bioorg. Med. Chem. Lett.16 (2006) 1164–1167; https://doi.org/10.1016/j.bmcl.2005.11.08710.1016/j.bmcl.2005.11.08716359863
- 16. B. Sharma, A. Verma, S. Prajapati and U. K. Sharma, Synthetic methods, chemistry, and the anticonvulsant activity of thiadiazoles, Int. J. Med. Chem.2013 (2013) Article ID 348948 (16 pages); https://doi.org/10.1155/2013/34894810.1155/2013/348948420745625405032
- 17. V. Mathew, J. Keshavayya, V. P. Vaidya and D. Giles, Studies on synthesis and pharmacological activities of 3, 6-disubstituted-1,2,4-triazolo [3,4-b]-1,3,4-thiadiazoles and their dihydro analogues, Eur. J. Med. Chem.42 (2007) 823–840; https://doi.org/10.1016/j.ejmech.2006.12.01010.1016/j.ejmech.2006.12.01017331622
- 18. İ. Celik, G. Ayhan-Kılcıgil, B. Guven, Z. Kara, A. S. Gurkan-Alp, A. Karayel and A. Onay-Besikci, Design, synthesis and docking studies of benzimidazole derivatives as potential EGFR inhibitors, Eur. J. Med. Chem.173 (2019) 240–249; https://doi.org/10.1016/j.ejmech.2019.04.01210.1016/j.ejmech.2019.04.01231009910
- 19. M. F. Abo-Ashour, W. M. Eldehna, A. Nocentini, H. S. Ibrahim, S. Bua, H. A. Abdel-Aziz, S. M. Abou-Seri and C. T. Supuran, Novel synthesized SLC-0111 thiazole and thiadiazole analogues: Determination of their carbonic anhydrase inhibitory activity and molecular modeling studies, Bioorg. Chem.87 (2019) 794–802; https://doi.org/10.1016/j.bioorg.2019.04.00210.1016/j.bioorg.2019.04.00230978604
- 20. D. I. Pérez, M. Pistolozzi, V. Palomo, M. Redondo, C. Fortugno, C. Gil, G. Felix, A. Martinez and C. Bertucci, 5-Imino-1,2,4-thiadiazoles and quinazolines derivatives as glycogen synthase kinase 3β (GSK-3β) and phosphodiesterase 7 (PDE7) inhibitors: determination of blood–brain barrier penetration and binding to human serum albumin, Eur. J. Pharm. Sci.45 (2012) 677–684; https://doi.org/10.1016/j.ejps.2012.01.00710.1016/j.ejps.2012.01.00722306656
- 21. Y. Bahmani, T. Bahrami and A. Alabadi, Synthesis, cytotoxicity assessment and molecular docking of n-(5-(substituted-benzylthio)-1,3,4-thiadiazole-2-yl)-2-p-fluorophenylacetamide derivatives as tyrosine kinase inhibitors, Indian J. Pharm. Sci. 81 (2019) 63–70.10.4172/pharmaceutical-sciences.1000480
- 22. A. S. Mayhoub, L. Marler, T. P. Kondratyuk, E. J. Park, J. M. Pezzuto and M. Cushman, Optimizing thiadiazole analogues of resveratrol versus three chemopreventive targets, Bioorg. Med. Chem.20 (2012) 510–520; https://doi.org/10.1016/j.bmc.2011.09.03110.1016/j.bmc.2011.09.031324895822115839
- 23. M. Varache-Lembege, S. Moreau, S. Larrouture, D. Montaudon, J. Robert and A. Nuhrich, Synthesis and antiproliferative activity of aryl- and heteroaryl-hydrazones derived from xanthone carbaldehydes, Eur. J. Med. Chem.43 (2008) 1336–1343; https://doi.org/10.1016/j.ejmech.2007.09.00310.1016/j.ejmech.2007.09.003
- 24. M. V. Berridge, P. M. Herst and A. S. Tan, Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction, Biotechnol. Annu. Rev.11 (2005) 127–152; https://doi.org/10.1016/S1387-2656(05)11004-710.1016/S1387-2656(05)11004-7
- 25. Ü. Demir Özkay, Ö. D. Can, B. N. Sağlık, U. Acar Çevik, S. Levent, Y. Özkay, S. Ilgın and Ö. Atlı, Design, synthesis, and AChE inhibitory activity of new benzothiazole–piperazines, Bioorg. Med. Chem. Lett.26 (2016) 5387–5394; https://doi.org/10.1016/j.bmcl.2016.10.04110.1016/j.bmcl.2016.10.04127789142
- 26. M. R. Haider, K. Ahmad, N. Siddiqui, Z. Ali, M. J. Akhtar, N. Fuloria, S. Fuloria, M. Ravichandran and M. S. Yar, Novel 9-(2-(1-arylethylidene)hydrazinyl)acridine derivatives: Target topoisomerase 1 and growth inhibition of HeLa cancer cells, Bioorg. Chem. 88 (2019) Article ID 102962; https://doi.org/10.1016/j.bioorg.2019.10296210.1016/j.bioorg.2019.10296231085373